GLP1R and cardiac hypertrophy: Here, we investigate the potential of Danuglipron (PF‐06882961, PF), a novel oral glucagon‐like peptide‐1 (GLP‐1) receptor agonist, in alleviating pressure overload (PO)‐induced cardiac hypertrophy and fibrosis.